Nagendran Sukumar
SEC CIK 1665124 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TSHA | Taysha Gene Therapies, Inc. | Pres, Head of R, D, Dir | 936.4K | $83.5K | $6.13M | 16 | 2022-02-02 | 2026-07-10 |
Most active insiders at TSHA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Nagendran Sukumar | Pres, Head of R, D, Dir | — | $5.33M |
| 2 | Nolan Sean P. | CEO, Dir | — | $840.2K |
| 3 | Alam Kamran | CFO | — | $492.5K |
| 4 | Long Alison S | Dir | — | — |
| 5 | Sepp-Lorenzino Laura | Dir | — | — |
| 6 | Stalfort John A III | Dir | — | — |
| 7 | Donenberg Phillip B. | Dir | — | — |
Transactions 16
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-07-10 18:54 | 2026-07-10 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | S - Sale | $6.24 | -200.0K | 936.4K | -18% | -$1.25M |
| DT | 2026-04-13 16:33 | 2026-04-10 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | M - OptEx | $1.71 | +19.0K | 1.34M | +1% | +$32.5K |
| DT | 2026-04-13 16:33 | 2026-04-10 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | S - Sale+OE | $4.46 | -200.0K | 1.14M | -15% | -$892.0K |
| M | 2026-01-27 | 2026-01-23+ | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | S - Sale | $4.72 | -116.0K | 1.32M | -8% | -$547.5K |
| DM | 2026-01-14 | 2026-01-12 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | M - OptEx | $1.15 | +200.0K | 1.12M | +22% | +$229.6K |
| D | 2026-01-14 | 2026-01-12 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | S - Sale+OE | $4.71 | -200.0K | 1.01M | -17% | -$942.0K |
| D | 2026-01-14 | 2026-01-12 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | A - Grant | $0.00 | +427.0K | 1.43M | +42% | $0 |
| DM | 2025-12-01 | 2025-11-28+ | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | S - Sale+OE | $4.58 | -370.2K | 1.01M | -27% | -$1.70M |
| DM | 2025-12-01 | 2025-11-28+ | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | M - OptEx | $1.52 | +370.2K | 1.27M | +41% | +$562.1K |
| D | 2025-09-12 | 2025-09-10 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | M - OptEx | $0.7 | +41.1K | 1.21M | +4% | +$28.8K |
| D | 2025-09-12 | 2025-09-10 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | S - Sale+OE | $3.23 | -200.0K | 1.01M | -17% | -$646.0K |
| 2025-08-22 | 2025-08-21 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | S - Sale | $2.85 | -57.1K | 1.17M | -5% | -$162.6K | |
| D | 2025-01-03 | 2025-01-02 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | A - Grant | $0.00 | +324.5K | 1.22M | +36% | $0 |
| D | 2024-01-04 | 2024-01-02 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | A - Grant | $0.00 | +863.6K | 897.8K | +2,523% | $0 |
| 2023-05-18 | 2023-05-16 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D, Dir | P - Purchase | $0.68 | +5,000 | 34.2K | +17% | +$3,400 | |
| 2022-02-03 | 2022-02-02 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Dir | P - Purchase | $8.01 | +10.0K | 29.2K | +52% | +$80.1K |
Purchase Sale Sale after option exercise All abbreviations